Need To Know: The Consensus Just Cut Its Beam Therapeutics Inc. (NASDAQ:BEAM) Estimates For 2027
Beam Therapeutics Inc. (NASDAQ:BEAM) recently saw its 2027 revenue estimates downgraded by analysts, causing a measurable cut to previous forecasts. The consensus of 14 analysts now projects US$26 million in revenue for 2027, an 82% reduction from the past 12 months' sales, and significantly less optimistic than the prior US$30 million estimate. This downgrade suggests a more conservative outlook for the company, with sales expected to decline while the broader industry anticipates growth.
Beam Therapeutics Inc. Stock 12‑Month Price Target Cut to $47.46, Implies 98% Upside
Analysts have cut Beam Therapeutics Inc.'s average 12-month price target to $47.46 from $48.93, with individual forecasts ranging from $26 to $80 per share. Despite the cut, this new target still implies a significant 98% potential upside based on the November 12 closing price. The consensus rating from 15 analysts remains a "Buy," with 13 buy ratings and 2 holds.
Does Pivotal Sickle Cell Trial Success Change The Bull Case For Beam Therapeutics (BEAM)?
Beam Therapeutics announced positive results from its BEACON Phase 1/2 trial for risto-cel, a sickle cell therapy, meeting all primary and secondary efficacy and safety endpoints. This success positions Beam for a potential first-of-its-kind FDA filing for a base editing therapy, strengthening the investment narrative around its "molecular pencil" platform. Despite the clinical success, the company remains pre-commercial, reporting a significant net loss and with no profitability expected in the next three years, highlighting ongoing funding and execution risks.
BEAM Stock Falls 7% Despite Meeting Primary Endpoints in SCD Study
Beam Therapeutics (BEAM) announced positive top-line results from its phase I/II BEACON study for ristoglogene autogetemcel (risto-cel), an investigational gene-editing therapy for sickle cell disease. The study met its primary efficacy and safety endpoints, with plans to submit a biologics license application (BLA) to the FDA by the end of 2026. Despite these encouraging results, BEAM's shares declined 7%, possibly due to concerns over third-quarter results, profit-taking, and regulatory uncertainties.
Wedbush maintains Beam Therapeutics at Outperform, raises price target to $33 from $30
Wedbush has reaffirmed its "Outperform" rating for Beam Therapeutics (BEAM) and increased its price target to $33 from $30, indicating a 10.0% rise. This new price target suggests an upside of 31.2% from the stock's closing price of $25.15 on November 10. Other analysts have recently issued price targets ranging from $30 to $80 for Beam Therapeutics.
Beam Therapeutics (BEAM) Dropped, So What Is Behind The Latest Attention?
Beam Therapeutics (BEAM) shares have seen short-term pressure despite positive news that its sickle cell therapy, risto-cel, met clinical trial endpoints and supports an FDA filing. The stock is considered 49% undervalued by analysts, with a fair value of $49.38, highlighting a debate over whether recent clinical progress is fully reflected in the current price. However, the company's Price-to-Sales ratio of 17.1x is higher than industry averages, suggesting a valuation anchored more in future optimism than current fundamentals.
Beam Therapeutics (BEAM) Clears A Key Trial As The Undervalued Case Faces A Test
Beam Therapeutics (BEAM) has achieved a significant clinical milestone with its sickle cell therapy candidate, ristoglogene autogetemcel, meeting all primary and secondary endpoints in the BEACON Phase 1/2 trial. Despite this success, the stock's short-term performance has been weak, though longer-term returns show some value retention. Analysts at Simply Wall St believe the stock is undervalued at $25.15, with a fair value of $49.38, pointing to differing views on its future earnings potential from gene-editing programs.
Beam's base-editing sickle cell therapy meets its goal in a pivotal trial, setting up a first-of-its-kind FDA filing
Beam Therapeutics announced positive topline pivotal data for risto-cel, its base-editing sickle cell therapy, which met the primary endpoint of freedom from severe vaso-occlusive crises for at least 12 months in the BEACON trial. This achievement positions Beam to submit a Biologics License Application to the FDA as early as the end of 2026, potentially marking the first base-editing therapy to reach this stage. While the company did not disclose the exact number of patients reaching the endpoint, detailed results are anticipated at a medical meeting in 2027, with earlier data presented at the American Society of Hematology meeting in December.
BEAM: Risto-cel nears BLA filing as in vivo editing programs advance
Beam Therapeutics is progressing with its gene-editing programs, with risto-cel's BLA filing targeted by year-end 2026 and launch expected in 2027 following positive BEACON trial results. Additionally, BEAM-302 is in pivotal development, and PKU and BEAM-301 are advancing as one-time gene-editing treatments. This information is based on Beam Therapeutics Inc.'s 3rd Annual Guggenheim Healthcare Innovation Conference.
Beam Therapeutics to seek approval of SCD cell therapy after trial success
Beam Therapeutics announced positive topline data from its Phase I/II BEACON trial for ristoglogene autogetemcel (risto-cel), a cell therapy for sickle cell disease (SCD). The therapy successfully met its primary and secondary endpoints, demonstrating freedom from severe vaso-occlusive crises for at least 12 consecutive months. Based on these results, Beam plans to submit a biologics license application (BLA) to the US FDA by the end of 2026, aiming to be the first base editing therapy approved.
Beam Therapeutics Announces Positive Topline Pivotal Data
Beam Therapeutics announced positive topline results from its BEACON Phase 1/2 trial for risto-cel, an investigational gene therapy for sickle cell disease. The study met its primary efficacy endpoint of freedom from severe vaso-occlusive crises for 12 consecutive months and all primary safety endpoints. These results support a planned U.S. Biologics License Application (BLA) submission for risto-cel as early as year-end 2026.
A sickle cell trial met its 12-month target for avoiding severe crises. A U.S. filing is expected by year-end.
Beam Therapeutics announced positive topline results from its BEACON Phase 1/2 trial for risto-cel in sickle cell disease, meeting the primary efficacy endpoint of freedom from severe vaso-occlusive crises for at least 12 consecutive months. The trial also met all primary safety and secondary efficacy endpoints. Following these results, Beam expects to submit a U.S. Biologics License Application for risto-cel as early as year-end 2026.
Beam Therapeutics Inc. (NASDAQ:BEAM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Beam Therapeutics Inc. (NASDAQ:BEAM) recently released disappointing third-quarter results, with revenues significantly missing expectations and losses increasing. Following these results, analysts have made serious cuts to their 2027 revenue outlook and anticipate higher losses per share. Despite the weaker earnings outlook, the average price target remained largely unchanged, potentially indicating an expectation that the long-term valuation will not be significantly impacted.
Beam Therapeutics Inc. (BEAM) Seasonal Returns Chart
The article provides a seasonal returns chart for Beam Therapeutics Inc. (BEAM), displaying the average monthly price return from 2020 to 2026. It shows the current stock price and after-hours trading information. The chart is part of Yahoo Finance's data and analysis tools for the company.
Guggenheim maintains Beam Therapeutics at Buy, lowers price target to $51 from $55
Guggenheim has reiterated its "Buy" rating for Beam Therapeutics (BEAM) but adjusted its price target downward from $55 to $51, representing a 7.3% decrease. Despite the reduction, the new price target still implies a significant upside of 83.5% from the previous day's closing price of $27.79. This latest analyst action follows other recent ratings from firms like Canaccord Genuity, Wedbush, and HC Wainwright & Co., with price targets ranging from $30 to $80 over the last 30 days.
Jones Trading initiates Beam Therapeutics stock coverage with buy rating
Jones Trading has initiated coverage on Beam Therapeutics (NASDAQ:BEAM) with a Buy rating and a $35.00 price target, citing the potential of BEAM-302 for alpha-1 antitrypsin deficiency. The firm projects significant peak sales for BEAM-302 and other pipeline assets, including sickle cell disease and phenylketonuria, contributing to their valuation. This positive outlook is supported by recent clinical trial advancements and strong liquidity, despite an InvestingPro analysis suggesting the stock may be overvalued at current levels.
Beam Therapeutics to Present Updated Clinical Data from BEACON Phase 1/2 Trial of Risto-cel in Sickle Cell Disease in an Oral Presentation at American Society of Hematology (ASH) Annual Meeting
Beam Therapeutics announced it will present updated clinical data from its BEACON Phase 1/2 trial of risto-cel in sickle cell disease (SCD) at the upcoming American Society of Hematology (ASH) Annual Meeting. The presentation will include initial patient-reported outcomes demonstrating early and sustained improvements in physical function, pain, fatigue, and overall well-being. The company anticipates submitting a U.S. Biologics License Application (BLA) for risto-cel as early as year-end 2026.
Beam Therapeutics (BEAM) Earnings Miss Puts Its Valuation Narrative To The Test
Beam Therapeutics (BEAM) recently reported a wider net loss and lower-than-expected revenue for Q3 2026, causing its shares to slide. Despite a narrative suggesting the stock is 47% undervalued with a fair value of $49.38, its current P/S ratio of 17.9x appears expensive compared to the biotech sector's 11x. The company's valuation hinges on its clinical pipeline, including BEAM-302 and BEAM-301, and how investors weigh potential program milestones against cash burn and current sales multiples.
Form 8K Beam Therapeutics Inc For: 3 November By Investing.com
Investing.com reported that Beam Therapeutics Inc. filed a Form 8K on November 3, 2026. The article is very brief and provides no additional details about the content of the Form 8K filing. It primarily serves as a notice of the filing.
Beam Therapeutics Reports Q3 2026 Results, $1.0 Billion in Cash
Beam Therapeutics announced a Q3 2026 net loss of $134.4 million but reported a strong cash position of $1.04 billion, with a projected cash runway into mid-2029. The company also highlighted significant clinical progress across its genetic disease and hematology programs, including updated data for BEAM-302 and BEAM-301, and plans for new trials and regulatory submissions.
$1B in cash and securities accompanies a wider Q3 loss at Beam Therapeutics (BEAM).
Beam Therapeutics reported a wider net loss of $134.405 million in Q3 2026, compared to $112.571 million in the same quarter last year, with license and collaboration revenue significantly decreasing. Despite the financial loss, the company holds $1.0 billion in cash, cash equivalents, and marketable securities, which it expects will fund operations for at least the next 12 months. Beam Therapeutics also provided updates on its clinical pipeline, including positive data from its BEAM-302 trial for AATD, BEAM-301 for GSDIa, and progress in its risto-cel program for sickle cell disease.
Form 8K Beam Therapeutics Inc For: 3 November By Investing.com
This article reports on Beam Therapeutics Inc's Form 8K filing for November 3rd. It notes that the company's stock, BEAM, was up 4.72% at the time of publication. The content indicates a standard financial filing report.
Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates
Beam Therapeutics Inc. (BEAM) reported a Q3 loss of $1.28 per share, missing the Zacks Consensus Estimate of $1.17, and revenues of $0.31 million, significantly below the $9.7 million from the previous year and the Zacks Consensus Estimate by 97.23%. The company's stock has underperformed the S&P 500 this year, leading to a Zacks Rank #4 (Sell) based on an unfavorable earnings outlook. Investors are advised to monitor future estimate revisions for potential stock movement.
Beam Therapeutics Q3 earnings: net loss widens to $134.4M | BEAM Stock News
Beam Therapeutics reported a net loss of $134.4 million in Q3 2026, widening from $112.6 million in the prior year, despite advancing its base editing clinical programs. Key updates include progress in BEAM-302 for AATD, BEAM-304 for PKU, and initial positive data from BEAM-301 for GSDIa, with a potential risto-cel BLA submission for sickle cell disease by year-end 2026. The company maintains an expected cash runway into mid-2029, supported by existing funds and anticipated additional borrowings.
Beam Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Clinical Progress Across Base Editing Portfolio
Beam Therapeutics announced its third-quarter 2026 financial results, ending the quarter with $1.0 billion in cash and equivalents, projected to last until mid-2029. The company highlighted significant clinical progress, including durable increases in AAT in the BEAM-302 trial, anticipated BLA submission for risto-cel in sickle cell disease by year-end 2026, and early clinical proof of concept for BEAM-301 in GSDIa. These milestones underscore the advancement of its precision genetic medicines pipeline.
Beam Therapeutics (BEAM) Stock Forecast & Analyst Ratings
This article provides an overview of Beam Therapeutics (BEAM) stock forecast and analyst ratings. It includes various metrics such as stock price targets, financial performance, and a summary of what analysts are predicting for the company's future. The information aims to help investors understand potential movements and valuations of BEAM stock based on expert opinions.
Beam Therapeutics surges 64% after InvestingPro’s undervalued call By Investing.com
Beam Therapeutics (NASDAQ:BEAM) saw its stock surge 64.51% after InvestingPro's Fair Value models identified it as significantly undervalued in April 2025 when it was trading at $17.64 per share. The gene editing biotech, which had an intrinsic value calculated at $26.37, reached $29.02 by September 2026, validating the analysis. The company's innovative platform and strong fundamental improvements, including a 145% revenue surge and improved EPS, contributed to its substantial gains.
Beam Therapeutics surges 64% after InvestingPro’s undervalued call By Investing.com
Beam Therapeutics (NASDAQ:BEAM) saw its stock price surge by 64.51% after InvestingPro's Fair Value models identified it as significantly undervalued in April 2025. The gene editing biotech, trading at $17.64 then, reached $29.02 in September 2026, validating the analysis. The company's innovative platform and strong fundamental improvements, including a 145% revenue surge and improved EPS, contributed to its success, attracting notable investors like Cathie Wood's ARK funds.
Cathie Wood Loads Up On TEM, ILMN And Biotech Stocks — But Pares Stake In This Pharma Giant That Had A Blowout Q3
Cathie Wood's ARK Invest made several significant trades, increasing its exposure to healthcare, genomics, and cryptocurrency stocks across its actively managed ETFs. Notably, ARK Genomic Revolution ETF and ARK Innovation ETF bought shares of Tempus AI and Illumina, along with other biotech companies. Conversely, ARK surprisingly pared its stake in pharmaceutical giant Eli Lilly, despite the company's strong third-quarter earnings.
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Beam Therapeutics (BEAM) and ProKidney (PROK)
Bank of America Securities analysts have provided updated ratings and price targets for several healthcare companies. Jason Zemansky reiterated a Hold rating on Biogen (BIIB) with a $255.00 price target, while Alec Stranahan maintained a Buy rating on Beam Therapeutics (BEAM) with a $43.00 price target. Dina Ramadane issued a Sell rating for ProKidney (PROK) with a $1.00 price target.
Canaccord Genuity maintains Beam Therapeutics at Buy, raises price target to $79 from $78
Canaccord Genuity has reiterated its Buy rating for Beam Therapeutics and increased its price target to $79 from $78. This new price target suggests a potential upside of 173.9% from the stock's closing price of $28.84 on October 29.
Beam Therapeutics Stock Has The Bull Case Changed After Early GSDIa Trial Results
Beam Therapeutics announced promising initial Phase 1/2 data for BEAM-301 in glycogen storage disease type Ia (GSDIa), showing dose-dependent improvements in fasting tolerance and reduced starch reliance. This early clinical signal strengthens Beam's liver disease franchise and base editing platform, potentially shifting the investment narrative from hypothesis to active regulatory planning. While financial risks and competition remain, analysts project significant revenue and earnings growth by 2029, with some suggesting a substantial upside to the current stock price.
Wedbush maintains Outperform rating on Beam Therapeutics, $28 price target
Wedbush has reiterated its Outperform rating for Beam Therapeutics' stock, setting a price target of $28.00, which suggests a 12.4% upside from its previous closing price. The analyst note highlights the company's strong pipeline of product candidates for serious conditions and positive early clinical data from ongoing trials as key factors.
Wedbush maintains Outperform rating on Beam Therapeutics, $28 price target
Wedbush has reiterated its Outperform rating for Beam Therapeutics, setting a price target of $28.00, which suggests a 12.4% upside from the previous day's closing price. This positive outlook is attributed to the company's strong pipeline of innovative therapies for serious conditions and encouraging early clinical data from its trials.
Beam Therapeutics Reports Early BEAM-301 Gains in GSD1a Fasting Tolerance
Beam Therapeutics announced positive early clinical data from its Phase I/II trial of BEAM-301 for glycogen storage disease type 1A (GSD1a), showing improved fasting tolerance and reduced cornstarch supplementation in treated patients. The 40 mg dose cohort demonstrated significant gains, with two out of three patients reaching the 15-hour fasting limit and eliminating cornstarch. The company plans to enroll patients in a 60 mg cohort and engage the FDA on a potential approval pathway, emphasizing the severity and rarity of the GSD1a R83C mutation.
Is Beam Therapeutics (BEAM) Undervalued On Early BEAM 301 Trial Results?
Beam Therapeutics (BEAM) released initial Phase 1/2 results for BEAM-301, showing dose-dependent effects and an acceptable safety profile, which led to a 4.67% share price increase in one day. Despite this, the year-to-date share price is down 8.25%, and the 5-year total shareholder return is significantly negative. The stock is currently trading at $24.90, which is considerably below a fair value estimate of $51.07, suggesting it is undervalued, but a high P/S ratio compared to the biotech average indicates investors are paying a premium for future potential.
Beam Therapeutics Reports Initial Clinical Data from Phase 1/2 Trial of BEAM-301, Demonstrating Proof of Concept for Genetic Correction in Glycogen Storage Disease Type Ia (GSDIa) at ESGCT 33rd Annual Congress
Beam Therapeutics reported initial Phase 1/2 clinical trial data for BEAM-301, its gene-editing therapy for glycogen storage disease type Ia (GSDIa). The results showed that two patients in the 40 mg cohort achieved 15 hours of controlled fasting and no longer required starch supplementation, indicating proof of concept for genetic correction and improved glucose control. The safety profile was consistent with LNP-based therapies, and Beam plans to discuss a potential approval pathway with the FDA.
BEAM Stock Climbs On First Look At One-Time GSDIa Gene Fix; H.C. Wainwright Sees Further 200% Upside
Beam Therapeutics (BEAM) shares rose over 4% after releasing initial clinical results from its BEAM-301 trial for glycogen storage disease type Ia (GSDIa). The one-time liver-targeted treatment showed promising results in improving blood sugar maintenance and reducing the need for starch supplementation in patients. H.C. Wainwright reiterated a 'Buy' rating and an $80 price target, seeing significant upside potential for Beam's platform.
Beam Therapeutics Reports Early BEAM-301 Gains in GSD1a Fasting Tolerance
Beam Therapeutics reported initial clinical data from its Phase I/II trial of BEAM-301 for glycogen storage disease type 1A (GSD1a), showing dose-dependent improvements in fasting tolerance and reduced cornstarch supplementation, especially in the higher-dose cohort. The investigational base-editing therapy demonstrated an acceptable safety profile, and the company plans to enroll patients in a 60 mg cohort to further evaluate safety and efficacy. Beam is also advancing its BEAM-304 program for phenylketonuria (PKU) and expects first PKU sites to open around late 2026 or early 2027.
Beam Therapeutics Reports Initial Clinical Data from Phase 1/2 Trial of BEAM-301, Demonstrating Proof of Concept for Genetic Correction in Glycogen Storage Disease Type Ia (GSDIa) at ESGCT 33rd Annual Congress
Beam Therapeutics announced initial Phase 1/2 clinical data for BEAM-301, an investigational gene-editing treatment for glycogen storage disease type Ia (GSDIa). The results showed that two of three patients in the 40 mg cohort achieved 15 hours of controlled fasting and no longer required daily starch supplementation. While four of six patients experienced serious treatment-related adverse events, the company plans to advance BEAM-301 into a 60 mg dose-escalation cohort and engage with the FDA regarding a potential approval path.
Beam Therapeutics Inc. Estimates – NASDAQ:BEAM
This article from TradingView provides an overview of Beam Therapeutics Inc. (NASDAQ:BEAM) financial data and analyst estimates. It highlights reported financial data and estimates across the income statement, balance sheet, cash flow statement, and valuation metrics, allowing users to compare actual results with average, high, and low estimates. The platform also offers visualization of trends over time for both annual and quarterly data.
Beam Therapeutics, Inc. Estimates – BMV:BEAM
This article provides an overview of Beam Therapeutics, Inc. (BMV:BEAM) financials and analyst estimates on TradingView. It highlights where to explore reported financial data and analyst estimates across various statements and valuation metrics. The page serves as a resource for comparing actual results with estimates and visualizing trends.
(BEAM) Movement as an Input in Quant Signal Sets
This article analyzes Beam Therapeutics Inc. (NASDAQ: BEAM) using proprietary quantitative signals, highlighting a neutral sentiment across all time horizons and an exceptional 63.4:1 risk-reward setup. It outlines three distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored to different risk profiles. The analysis suggests a wait-and-see approach due to a mid-channel oscillation pattern and provides specific entry, target, and stop-loss parameters.
Does Ark Buying More Shares Change The Bull Case For Beam Therapeutics (BEAM)?
Ark ETFs, led by Cathie Wood, recently increased their stake in Beam Therapeutics by US$2.8 million, boosting the biotech's visibility. This investment highlights Beam Therapeutics' base editing platform and partnerships with Pfizer and Eli Lilly as crucial for its commercialization path. The article explores how this increased ownership might influence the investment narrative, though the core operational story still hinges on clinical progress and addressing safety concerns around conditioning.
Beam Therapeutics (BEAM) After BEAM 302 Data And Probe Is The Undervaluation Case Broken
Beam Therapeutics (BEAM) is facing legal scrutiny and a stock price drop following updated BEAM-302 clinical data, leading to investor reevaluation of clinical opportunities and legal risks. Despite a narrative of being 54% undervalued based on its pipeline potential and ESCAPE technology, another perspective views the stock as expensive at 15x sales compared to industry averages. The mixed signals present a complex situation for investors to assess the company's true valuation and future prospects.
Beam Therapeutics (BEAM) After BEAM 302 Data And Probe Is The Undervaluation Case Broken
Beam Therapeutics (BEAM) is facing legal scrutiny and a share price drop following updated BEAM-302 clinical data, despite being considered 54% undervalued based on its pipeline progress and fair value estimate of $51.07. However, an alternative view suggests the company looks expensive on sales, with a P/S ratio of 15x compared to the industry average of 11.1x. Investors are urged to consider both the growth narrative and potential risks, including safety setbacks or slow trial progress.
Beam Therapeutics CEO John Evans sells $1.19m in company stock
Beam Therapeutics CEO John Evans sold approximately $1.19 million worth of company stock across two days, October 15 and 16, 2026, under a pre-arranged Rule 10b5-1 trading plan. These transactions involved exercising options to acquire shares at a low price and then selling them at market prices. Following these sales, Evans still holds over 1 million direct shares and additional shares through a trust, while the company progresses with clinical trials and maintains an analyst "Buy" rating despite current overvaluation according to InvestingPro.
Form 4 Beam Therapeutics Inc: John M. Evans (Director, CEO) For: 15 October By Investing.com
This article reports a Form 4 filing for Beam Therapeutics Inc., indicating that John M. Evans, who serves as both a Director and CEO, was involved in a transaction on October 15. The brief piece primarily serves as an alert for insider trading activity without providing further details on the nature of the transaction.
Form 4 Beam Therapeutics Inc: John M. Evans (Director, CEO) For: 15 October
This article reports on a Form 4 filing for Beam Therapeutics Inc., indicating a transaction by John M. Evans, who holds roles as Director and CEO. The filing pertains to activity on October 15. The article provides minimal details beyond this notification.
Form 4 Beam Therapeutics Inc: John M. Evans (Director, CEO) For: 15 October
This article reports on a Form 4 filing for Beam Therapeutics Inc., indicating a transaction by John M. Evans, who holds roles as Director and CEO. The filing pertains to an event on October 15th, providing a standard update on insider trading activity for the company BEAM.